企業プロフィール
Sana Biotechnology 株価・ニュース・カタリスト
- ティッカー:
- SANA
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
3.74 USD (-8.78%)
終値
最終更新: 2026年8月20日
902M USD
時価総額
株価変動の要因
As of Aug 20, 2026, SANA closed down 8.78% at $3.74. No new same-company headline was identified in the current news window.
企業概要
Engineered Cell Therapies
Sana Biotechnology develops engineered cells intended to repair or replace damaged biology while overcoming immune rejection. Its platform spans ex vivo cell replacement and in vivo delivery technologies.
SC451 Islet-Cell Therapy
SC451 is a gene-modified, stem-cell-derived pancreatic islet-cell candidate designed to restore insulin production in people with type 1 diabetes without chronic immunosuppression. Sana is advancing the program in collaboration with Mayo Clinic.
UP421 Clinical Validation
UP421 is a hypoimmune-modified primary islet-cell therapy being evaluated in an investigator-sponsored study without immunosuppression. Survival and insulin-producing function observed after transplantation provide human validation for the immune-evasion technology used in SC451.
SG293 In Vivo CAR-T
SG293 uses a CD8-targeted fusosome to deliver genetic material that creates CD19-directed CAR-T cells inside the body. Sana plans to begin in non-Hodgkin lymphoma before potentially expanding into B-cell-mediated autoimmune diseases.
SG227 Multiple-Myeloma Program
SG227 applies the same in vivo delivery approach to a BCMA-directed CAR for multiple myeloma. Its clinical entry is contingent on the initial safety and efficacy profile of SG293.
今後のカタリスト
- IND submission and Phase 1/2 initiation for SC451 as early as 2026.
- First-in-human data for SG293 in non-Hodgkin lymphoma as early as 2026.
- Additional UP421 investigator-sponsored-study data at the EASD Annual Meeting on October 2, 2026.
- Clinical-study initiation for SG227 as early as mid-2027, contingent on the early SG293 clinical profile.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。